Great Neck, NYNCT07061847Now EnrollingIRB Ready

Migraine Clinical Trial in Great Neck, NY

Access cutting-edge migraine treatment through this phase 2 clinical trial at a research site in Great Neck. Study-provided care at no cost to qualified participants.

Sponsored by Northwell Health

Quick Self-Assessment

See if you qualify for this Great Neck location

Preparing your pre-screening questions…

Expert Care in Great Neck

Access migraine specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related migraine treatment provided free

Apply for This Great Neck Location

Check if you qualify for this migraine clinical trial in Great Neck, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Great Neck

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Great Neck site if eligible
  4. 4Begin participation

About This Migraine Study in Great Neck

The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, frequency, and duration.

Sponsor: Northwell Health

Who Can Participate

Inclusion Criteria

Adults aged 18 to 75 years with a very severe to extremely severe medically refractory Chronic Daily Headache (CDH).
Chronic: as defined by the International Headache Society Classification ICHD 3 (\>15 headache days a month for a period of at least 3 months)
Medically refractory: defined as failure of ≥3 headache preventative treatments.
Severely disabling (Migraine Disability Assessment \[MIDAS\] Tool score of ≥ 21 \[Grade IV\])
Score of 6 (very severe) or 7 (extremely severe) on the Global Assessment of Migraine Severity (GAMS) rating scale.
Head pain is at least moderate-to-severe intensity (\>5 on a Visual Analog Scale) in ≥50% of headaches.
Diagnosis of CDH for ≥ 12 months before screening based on medical records and/or patient self-report.
Headache frequency: minimum 15 monthly headache days (MHD) on average across the 3 months prior to screening
Patient reports to their provider intolerance or insufficient response with their current preventive treatment (i.e. insufficient reduction in headache frequency, duration, and severity on a standard treatment on a generally accept therapeutic dose for 6 weeks).
On a stable concomitant medication and headache preventive for the 3 months prior to screening During Baseline Period:
Must have ≥ 15 MHD based on the patient self-maintained diary data during the baseline period.
Must have demonstrated \>75% compliance with diary data for the 28 day duration period, or longer if their baseline period carries on past this point.
Must continue to meet eligibility criteria when reassessed at baseline completion visit

Exclusion Criteria

Recently started new migraine preventative treatment regimen within the past 3 months.
Known allergy or sensitivity to lidocaine.
Lidoderm patch (not an exclusion if the Lidoderm patch has been removed for ≥ 3 days before the procedure)
Severe allergy/anaphylaxis to iodinated contrast dye.
Any intracranial pathology on brain imaging (head CT or MRI within the past 12 months)
Chronic subdural hematoma
Ischemic stroke or myocardial infarction within 3 months 8. History of renal insufficiency with Cr \> 1.5 within 3 months (will be retested during pre-surgical testing). 9\. History of abnormal ECGs within 3 months, specifically:
Prolonged QT syndrome
Use of medications that may prolong the QT interval such as: anti-nausea, anti-emetics, etc. 10\. Taking any antiarrhythmic medication (other than a beta blocker) 11\. Symptomatic peripheral arterial disease 12\. Known inherited or acquired bleeding diathesis (not including antiplatelet or anticoagulation medication) 13\. Evidence of active substance-related disorders, addictive disorders, or "recreational use" of illicit drugs. a. If any of these disorders have occurred within 12 months prior to screening, based on medical records, patient self-report, or positive urine drug test (except for prescribed medications that may result in a positive urine drug test). 14\. Active chronic pain syndromes (e.g., fibromyalgia and chronic pelvic pain). 15\. History of major psychiatric disorder or current evidence of moderately severe or severe depression based on a Patient Health Questionnaire-9 (PHQ-9) total score ≥ 15 at screening. a. Subjects with history of anxiety disorder and/or major depressive disorder with PHQ-9 \< 15) and are taking no more than 1 medication, for each disorder, for at least 2 months prior to screening may be considered. 16\. If the subject is pregnant, planning on pregnancy during the duration of the study, or planning on making their partner pregnant will be excluded from the study unless proper contraception is in place. 17\. Any diagnosis at the discretion of the investigator that would make the patient unfit.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Great Neck?

Yes, this clinical trial (NCT07061847) has an active research site in Great Neck, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Migraine Treatment Options in Great Neck, NY

If you're searching for migraine treatment options in Great Neck, NY, this clinical trial (NCT07061847) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Great Neck research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced migraine specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all migraine clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Great Neck, NY

See all heart attack clinical trials recruiting in Great Neck — not just this study.

Browse Heart Attack Trials in Great Neck →

Browse More Trials by Condition

Heart Attack TrialsMigraine TrialsRheumatoid Arthritis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Great Neck?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Great Neck, NY